Format

Send to

Choose Destination
Pediatr Infect Dis J. 2019 Feb;38(2):e26-e28. doi: 10.1097/INF.0000000000002045.

Safety, Effectiveness and Exposure-response of Micafungin in Infants: Application of an Established Pharmacokinetics Model to Electronic Health Records.

Author information

1
From the Duke Clinical Research Institute.
2
Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina.
3
Department of Pediatrics, Penn State College of Medicine, Hershey, Pennsylvania.
4
Pediatrix Medical Group, Inc., Sunrise, Florida.

Abstract

Micafungin is used off-label in the United States to treat invasive candidiasis in neonates. We used an established pharmacokinetic model to determine micafungin exposures for 46 courses in 39 hospitalized infants. In this small cohort of infants, micafungin exposure was not associated with laboratory markers of liver toxicity, death or failure of microbiologic clearance.

PMID:
29601453
PMCID:
PMC6163100
[Available on 2020-02-01]
DOI:
10.1097/INF.0000000000002045

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center